Update on Small-Cell Lung Cancer

February 28th 2020

Relapsed or Refractory Metastatic CRC

February 25th 2020

Evolution of Predictive Biomarkers for Metastatic CRC

February 8th 2020

Phase III ALTA-1L Trial of Brigatinib for ALK-Rearranged NSCLC

February 4th 2020

Emerging Therapies in HER 2-Positive Metastatic Breast Cancer

January 11th 2020

Practical Management of Patients with Neuroendocrine Tumors

December 13th 2019

New Indications for AR-Targeted Therapy on Prostate Cancer: Including ESMO 2019 Highlights

November 14th 2019

Expanding Targets in NSCLC

October 24th 2019

How Systemic Therapy is Combating Advanced CSCC

October 24th 2019

The Future of RET Inhibitors in Non-Small Cell Lung and Thyroid Cancer

October 18th 2019

Navigating the Complexities of HCC

September 10th 2019

Inside the Clinic: Acute Graft-versus-Host Disease

August 2nd 2019

Key Considerations for Detecting and Targeting BRAF Mutations

July 31st 2019

TRK Inhibitors: Evolution of a Tumor-Agnostic Treatment Approach

July 30th 2019

Whats Next? Sequencing Later-Line Therapies in Metastatic CRC

July 15th 2019

Advances in Treatment for ALK-Positive NSCLC

July 12th 2019

Frontline Therapy In Follicular Lymphoma

July 9th 2019

AFP as a Prognostic and Predictive Marker in HCC

June 17th 2019

Inside the Clinic: Global Insights: Multidisciplinary Care of Stage III NSCLC

May 2nd 2019

Expanding Role of PARP Inhibitors in Advanced Ovarian Cancer

April 29th 2019